Putting Data into Practice: Applying the Latest Clinical Evidence to Management Strategies

This activity is part of a series

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School
Columbia, SC
Medical University of South Carolina
Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.

Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS
Professor of Neurology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Sleep Disorders Center, Cleveland, OH
Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS

Dr. Nancy Foldvary-Schafer currently serves as Director of the Sleep Disorders Center and staff in the Adult Epilepsy Center at the Cleveland Clinic in Cleveland, Ohio. She is Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Certified by the American Board of Neurology and Psychiatry in Neurology, Clinical Neurophysiology, Sleep Medicine and Epilepsy Medicine, she has treated patients with sleep disorders and epilepsy at the Cleveland Clinic since 1995. Under her leadership, the Cleveland Clinic Sleep Medicine program has undergone substantial growth including the establishment of 10 sleep laboratories and a multidisciplinary physician team spanning across neurology, psychiatry, psychology, pulmonary medicine, family and internal medicine, and pediatric specialties. She has served as a lead investigator on epilepsy, sleep apnea and narcolepsy clinical trials and has written extensively on sleep and epilepsy and women’s health and epilepsy. In 2016, Dr. Foldvary-Schaefer was appointed to the Cleveland Clinic Board of Governors. She serves on numerous national, regional, and local committees and is the author of two books and the lead editor of two books including Sleep Disorders: A Case a Week from the Cleveland Clinic, 2nd Edition, published in 2019. Also, in 2019, she received the Women’s Professional Staff Association Champion Award. She is the recipient of a $2.1 million philanthropic gift to advance education and awareness of sleep disorders.

Statement of Need

Excessive daytime sleepiness (EDS) has a far-reaching impact, affecting not just quality of life (QoL) but also work, school, and psychosocial functioning. EDS is highly comorbid and can exacerbate medical and psychiatric conditions, both of which require clinicians to be aware of effective therapies to reduce the severity and impact of persistent sleepiness.

The final installment of this 3-part journal club series hosted by CME Outfitters highlights the latest clinical evidence on novel therapies for EDS in obstructive sleep apnea (OSA) and narcolepsy and how to incorporate this evidence into optimal treatment planning to reduce the burden of EDS.

Learning Objectives

At the end of this CME/CE activity, participants should be able to incorporate the latest clinical evidence on novel therapies for EDS in OSA and narcolepsy into optimal treatment planning to reduce the illness burden.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, PCPs, PAs, NPs, nurses, pharmacists.

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

Note to PAs

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit  from organizations accredited by the Accreditation Council for Continuing Medical Education.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.


Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.


Dr. Foldvary-Schaefer reports that she receives research support Jazz Pharmaceuticals, Inc.; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. She is on the advisory committee for Jazz Pharmaceuticals. She is a consultant for Jazz Pharmaceuticals, Inc Publication Committee.


Tony Graham, MD (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.


Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

 


NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-105-H01-P

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

 

 


JC-021-032321-43

 

Putting Data into Practice: Applying the Latest Clinical Evidence to Management Strategies
Event Date: 01/01/2023